Log in to save to my catalogue

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (...

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2440285563

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

About this item

Full title

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

Publisher

San Francisco: Public Library of Science

Journal title

PloS one, 2020-09, Vol.15 (9), p.e0237497-e0237497

Language

English

Formats

Publication information

Publisher

San Francisco: Public Library of Science

More information

Scope and Contents

Contents

Background Eculizumab has transformed management of paroxysmal nocturnal hemoglobinuria (PNH) since its approval. However, its biweekly dosing regimen remains a high treatment burden. Ravulizumab administered every 8 weeks demonstrated noninferiority to eculizumab in two phase 3 trials. In regions where two PNH treatment options are available, it i...

Alternative Titles

Full title

Patient preferences and quality of life implications of ravulizumab (every 8 weeks) and eculizumab (every 2 weeks) for the treatment of paroxysmal nocturnal hemoglobinuria

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_2440285563

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2440285563

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0237497

How to access this item